Last reviewed · How we verify
Bivalent influenza vaccine
At a glance
| Generic name | Bivalent influenza vaccine |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers (EARLY_PHASE1)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza (PHASE2)
- Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
- A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV). (PHASE2)
- Effects of Prompt to Bundle COVID-19 Booster and Flu Shot (NA)
- This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.
- Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines (PHASE4)
- D2560C00015 FluMist Annual Safety Study 2018 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bivalent influenza vaccine CI brief — competitive landscape report
- Bivalent influenza vaccine updates RSS · CI watch RSS
- MedImmune LLC portfolio CI